Skip to main content
Journal of Patient-Reported Outcomes
Fig. 5 | Journal of Patient-Reported Outcomes

Fig. 5

From: Real-world use and clinical impact of an electronic patient-reported outcome tool in patients with solid tumors treated with immuno-oncology therapy

Fig. 5

Estimated OS. a HC vs ePRO cohort, b ePRO cohort users vs non-users, and c) monotherapy vs combination therapy subgroups for first IO regimen. aPatients who did not die or had unknown death date were censored at date of last contact with TO). Kaplan-Meier curves were truncated at 6 months from the index date, the maximum observation period. Shaded areas around the curves represent 95% CIs. CI confidence interval; Comb combination therapy; ePRO electronic patient-reported outcome; HC historical control; IO immuno-oncology; M month; Mono monotherapy; NE not estimable; OS overall survival; Pts patients; TO Tennessee oncology; TTE time to event

Back to article page